Core Viewpoint - Zhejiang Securities Regulatory Bureau issued regulatory warnings to Minsheng Securities and two sponsoring representatives due to violations during the continuous supervision of Zhejiang Weikang Pharmaceutical's IPO process [1] Group 1: Violations Identified - Minsheng Securities failed to adequately monitor the abnormal delays in construction projects, indicating insufficient verification procedures [1] - The conclusions drawn in the continuous supervision documents for Weikang Pharmaceutical's 2023 annual report were not cautious enough, revealing deficiencies in internal controls within the investment banking operations [1] Group 2: Regulatory Framework - The actions of Minsheng Securities violated Article 5, Paragraph 1 of the "Administrative Measures for Sponsoring Business of Securities Issuance and Listing" (CSRC Order No. 170) [1] - The sponsoring representatives, Ren Shaozhong and Zhong Desong, bear primary responsibility for the aforementioned violations [1]

Core Points - Zhejiang Securities Regulatory Bureau issued a decision regarding Minsheng Securities for violations during the continuous supervision of Weikang Pharmaceutical's IPO [1] - Minsheng Securities failed to adequately monitor the abnormal delays in construction projects and lacked sufficient verification procedures [1] - The internal controls of the investment banking business were found to be deficient, leading to insufficiently cautious conclusions in the continuous supervision documents for Weikang Pharmaceutical for the year 2023 [1] - The actions of Minsheng Securities violated the Securities Issuance and Listing Sponsorship Business Management Measures [1] - The responsible representatives, Ren Shaozhong and Zhong Desong, were held primarily accountable for the violations [1] - As a result, the Zhejiang Securities Regulatory Bureau decided to issue a warning letter as an administrative regulatory measure [1]